76 results
8-K
EX-10.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
424B4
50v 7tskr
18 Oct 22
Prospectus supplement with pricing info
7:01am
8-K
EX-10.3
1ytksqgos9qb
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
trmnezf1kfq wf
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.1
5p3ao kv20y97
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
S-3
EX-4.5
ov4yoibricvm
26 Jan 22
Shelf registration
4:15pm
S-3
EX-4.6
g5xyk6n
26 Jan 22
Shelf registration
4:15pm
S-3
EX-1.2
9xbaa g6psg73wq
26 Jan 22
Shelf registration
4:15pm
424B3
ma69jf78
16 Aug 21
Prospectus supplement
4:17pm
424B3
8u5u2i2
16 Aug 21
Prospectus supplement
4:17pm